GlassScriptPhysician profile
Tandy S Repass
NPI 1043444219
$8,711.28
in general payments reported to CMS, 2019-2025
29 companies · $2,593 in 2025
The $2,593 reported for 2025 was more than what 82% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $211 · 2022: $1,583 · 2023: $1,978 · 2024: $2,346 · 2025: $2,593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,659 · Education: $258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,658.98 |
| Education | $258.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,886.69 | 2021-2025 | |
| Janssen Biotech, INC. | $1,664.15 | 2022-2025 | Tremfya |
| Lilly USA, LLC | $842.32 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $533.62 | 2022-2025 | Sotyktu, Sprycel |
| Regeneron Healthcare Solutions, INC. | $512.37 | 2021-2025 | Dupixent, Libtayo |
| Amgen INC. | $395.15 | 2021-2025 | Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $359.86 | 2022-2025 | Spevigo, Cyltezo |
| Sun Pharmaceutical Industries INC. | $277.49 | 2021-2025 | Blu-U, Odomzo, Absorica Ld |
| Genzyme Corporation | $266.29 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $259.93 | 2023-2025 | Zoryve |
| Pfizer INC. | $250.31 | 2022-2024 | |
| Leo Pharma INC. | $213.38 | 2022-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $197.22 | 2023-2025 | |
| Ucb, INC. | $154.94 | 2022-2025 | Bimzelx |
| Incyte Corporation | $123.55 | 2021-2024 | Opzelura |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $107.88 | 2022-2024 | Klisyri |
| Dermavant Sciences, INC. | $95.03 | 2023-2024 | Vtama |
| Genentech USA, INC. | $94.47 | 2021-2023 | Erivedge |
| Stemline Therapeutics INC. | $83.59 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $68.85 | 2022-2025 | Cabtreo |
| Galderma Laboratories, L.P. | $62.46 | 2022-2025 | Aklief |
| Biofrontera INC. | $55.87 | 2022-2025 | Ameluz, Rhodoled Xl, Xepi |
| Organogenesis INC. | $47.62 | 2023-2025 | Puraply, Via Matrix |
| Lnhc, INC | $46.66 | 2025 | Zelsuvmi |
| Convatec INC. | $40.36 | 2024 | |
| Journey Medical Corporation | $21.36 | 2025 | |
| Fresenius Kabi USA, LLC | $17.10 | 2023 | Idacio |
| Botanix Sb INC | $17.04 | 2025 | Sofdra |
| Organon LLC | $15.72 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tandy Repass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.